User profiles for Michael Kreuter
Michael KreuterMainz Center for pulmonary diseases, University of Mainz and Marienhaus Klinikum Mainz … Verified email at marienhaus.de Cited by 16546 |
SARS‐CoV‐2 receptor ACE 2 and TMPRSS 2 are primarily expressed in bronchial transient secretory cells
…, C Veith, AW Boots, BP Hennig, M Kreuter… - The EMBO …, 2020 - embopress.org
The SARS ‐CoV‐2 pandemic affecting the human respiratory system severely challenges
public health and urgently demands for increasing our understanding of COVID ‐19 …
public health and urgently demands for increasing our understanding of COVID ‐19 …
Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline
…, Y Inoue, T Johkoh, M Kreuter… - American Journal of …, 2022 - atsjournals.org
Background: This American Thoracic Society, European Respiratory Society, Japanese
Respiratory Society, and Asociación Latinoamericana de Tórax guideline updates prior …
Respiratory Society, and Asociación Latinoamericana de Tórax guideline updates prior …
Diagnosis of hypersensitivity pneumonitis in adults: an official ATS/JRS/ALAT clinical practice guideline
…, CJ Ryerson, JL Myers, M Kreuter… - American journal of …, 2020 - atsjournals.org
Background: This guideline addresses the diagnosis of hypersensitivity pneumonitis (HP). It
represents a collaborative effort among the American Thoracic Society, Japanese …
represents a collaborative effort among the American Thoracic Society, Japanese …
Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo …
Background Pirfenidone has been shown to slow disease progression in patients with
idiopathic pulmonary fibrosis (IPF). However, there are few treatment options for progressive …
idiopathic pulmonary fibrosis (IPF). However, there are few treatment options for progressive …
[HTML][HTML] Global incidence and prevalence of idiopathic pulmonary fibrosis
Background Idiopathic pulmonary fibrosis (IPF) is a progressive debilitating lung disease
with considerable morbidity. Heterogeneity in epidemiologic studies means the full impact of …
with considerable morbidity. Heterogeneity in epidemiologic studies means the full impact of …
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial
Background At present, no approved pharmacotherapies are available for unclassifiable
interstitial lung disease (ILD), which is characterised by progressive fibrosis of the lung. We …
interstitial lung disease (ILD), which is characterised by progressive fibrosis of the lung. We …
Outcome of hospitalization for COVID-19 in patients with interstitial lung disease. An international multicenter study
Rationale: The impact of coronavirus disease (COVID-19) on patients with interstitial lung
disease (ILD) has not been established. Objectives: To assess outcomes in patients with ILD …
disease (ILD) has not been established. Objectives: To assess outcomes in patients with ILD …
[HTML][HTML] Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype
…, A Shimizu, A Kaipainen, M Kreuter… - The Journal of …, 2004 - Am Soc Clin Investig
Melanoma is the most lethal skin cancer. Most deaths from melanoma result from metastases.
Semaphorins have been shown to inhibit neuronal and endothelial cell migration, but the …
Semaphorins have been shown to inhibit neuronal and endothelial cell migration, but the …
Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities
Within the spectrum of fibrosing interstitial lung diseases (ILDs) is a subset of patients who
have inexorable progression of pulmonary fibrosis despite treatment, which is known as the …
have inexorable progression of pulmonary fibrosis despite treatment, which is known as the …
[HTML][HTML] Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical …
Patients with cancer are at high risk of severe coronavirus disease 2019 (COVID-19), with
high morbidity and mortality. Furthermore, impaired humoral response renders severe acute …
high morbidity and mortality. Furthermore, impaired humoral response renders severe acute …